nach oben

Journal of Genetic Counseling

Erschienen in:

01.02.2014 | Original Research

Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors

verfasst von: Stephanie A. Cohen

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

An electronic survey of the National Society of Genetic Counselors Cancer Special Interest Group was conducted in July 2011 to assess Lynch syndrome tumor screening programs and identify barriers to implementation. Over half of respondents (52.8 %) reported having a routine Lynch syndrome tumor screening protocol for newly diagnosed colon and/or endometrial cancers, and approximately half of these used a universal approach. There was an increase in the number of those screening over time, especially in the past 3 years. Tumor screening methods varied; 34/53 (64.2 %) started with immunohistochemistry, 11/53 (20.8 %) started with microsatellite instability testing and 8/53 (15.1 %) performed both on newly diagnosed colorectal tumors. Just 21.7 % (23/106) of respondents indicated they have a tumor screening program in place for newly diagnosed endometrial cancers. Written consent is rarely obtained (7.1 %) and the method of how results were returned to the patient was variable among respondents. Prevalent barriers to implementation were concern about cost, bringing key players together and convincing medical staff of the necessity. Use of Lynch syndrome tumor screening is in clinical practice, but protocols vary widely. This survey provides a glimpse of current practices and common barriers, and identifies the need for tumor screening algorithms with outcomes data.

Backes, F. J., Mitchell, E., Hampel, H., & Cohn, D. E. (2011). Endometrial cancer patients and compliance with genetic counseling: room for improvement. Gynecologic Oncology. doi:10.1016/j.ygyno.2011.09.002.

Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2010). Risks of lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201. doi:10.1093/jnci/djp473.PubMedCrossRef

Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763. doi:10.1056/NEJMoa053493.PubMedCrossRef

Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242. doi:10.1111/j.1399-0004.2008.01035.x.PubMedCrossRef

Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141–149. doi:10.1111/j.1399-0004.2008.01125.x.PubMedCrossRef

Beamer, L., Grant, M., Espenschied, C., Blazer, K., Hampel, H., Weitzel, J., et al. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology, 30(10), 1058–1063.PubMedCrossRef

Bellcross, C. A., Bedrosian, S. R., Daniels, E., Duquette, D., Hampel, H., Jasperson, K., et al. (2012). Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 14(1), 152–162.PubMedCentralPubMedCrossRef

Bellizzi, A. M., & Frankel, W. L. (2009). Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Advances in Anatomic Pathology, 16(6), 405–417. doi:10.1097/PAP.0b013e3181bb6bdc.

Bouzourene, H., Hutter, P., Losi, L., Martin, P., & Benhattar, J. (2010). Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Familial Cancer, 9(2), 167–172. doi:10.1007/s10689-009-9302-4.PubMedCrossRef

Burks, R. T., Kessis, T. D., Cho, K. R., & Hedrick, L. (1994). Microsatellite instability in endometrial carcinoma. Oncogene, 9(4), 1163–1166.PubMed

Burt, R. W., Giardiello, F. M., Jasperson, K., Lynch, P. M., Steinbach, G. (2011). NCCN Guidelines v.2.2011 Colorectal Cancer Screening. www.nccn.org. Accessed 3-1-2012 2012.

Byfield, S. A., & Syngal, S. (2008). Clinical guidelines versus universal molecular testing: are we ready to choose an optimal strategy for Lynch syndrome identification? American Journal of Gastroenterology, 103(11), 2837–2840. doi:10.1111/j.1572-0241.2008.02091.x.PubMedCrossRef

Chubak, B., Heald, B., & Sharp, R. R. (2011). Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(4), 356–360. doi:10.1097/GIM.0b013e31820aee09.

Cunningham, J. M., Christensen, E. R., Tester, D. J., Kim, C.-Y., Roche, P. C., Burgart, L. J., et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Research, 58(15), 3455–3460.PubMed

Des Guetz, G., Schischmanoff, O., Nicolas, P., Perret, G.-Y., Morere, J.-F., & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. European Journal of Cancer, 45(10), 1890–1896. doi:10.1016/j.ejca.2009.04.018.PubMedCrossRef

Dove-Edwin, I., Sasieni, P., Adams, J., & Thomas, H. J. (2005). Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 331(7524), 1047. doi:10.1136/bmj.38606.794560.EB.PubMedCrossRef

EGAPP. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.CrossRef

Evans, D. G., Walsh, S., Hill, J., & McMahon, R. T. (2007). Strategies for identifying hereditary nonpolyposis colon cancer. Seminars in Oncology, 34(5), 411–417. doi:10.1053/j.seminoncol.2007.07.001.PubMedCrossRef

Fitzgibbons, R. J., Jr., Lynch, H. T., Stanislav, G. V., Watson, P. A., Lanspa, S. J., Marcus, J. N., et al. (1987). Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Annals of Surgery, 206(3), 289–295.PubMedCrossRef

Garg, K., & Soslow, R. A. (2009). Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. Journal of Clinical Pathology, 62(8), 679–684. doi:10.1136/jcp.2009.064949.PubMedCrossRef

Gudgeon, J., Williams, J., Burt, R. W., Samowitz, W., Snow, G., & Williams, M. (2011). Lynch syndrome screening implementation: business analysis by a healthcare system. The American Journal of Managed Care, 17(8), e288–e300.PubMed

Hall, M. J. (2010). Counterpoint: implementing population genetic screening for lynch syndrome among newly diagnosed colorectal cancer patients—will the ends justify the means? Journal of the National Comprehensive Cancer Network, 8(5), 606–611.

Hampel, H. (2010). Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network, 8(5), 597–601.PubMed

Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860. doi:10.1056/NEJMoa043146.PubMedCrossRef

Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J.-P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later Age of onset. Gastroenterology, 129(2), 415–421. doi:10.1053/j.gastro.2005.05.011.PubMed

Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810–7817. doi:10.1158/0008-5472.CAN-06-1114.PubMedCrossRef

Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2008). Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology, 26(35), 5783–5788. doi:10.1200/JCO.2008.17.5950.PubMedCrossRef

Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences, 95(12), 6870–6875.CrossRef

Jarvinen, H. J., Renkonen-Sinisalo, L., Aktan-Collan, K., Peltomaki, P., Aaltonen, L. A., & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology, 27(28), 4793–4797. doi:10.1200/JCO.2009.23.7784.PubMedCrossRef

Karlan, B. Y., Berchuck, A., & Mutch, D. (2007). The role of genetic testing for cancer susceptibility in gynecologic practice. Obstetrics and Gynecology, 110(1), 155–167. doi:10.1097/1001.AOG.0000269050.0000279143.0000269084.PubMedCrossRef

Kwon, J. S., Scott, J. L., Gilks, C. B., Daniels, M. S., Sun, C. C., & Lu, K. H. (2011). Testing women with endometrial cancer to detect lynch syndrome. Journal of Clinical Oncology, 29(16), 2247–2252. doi:10.1200/jco.2010.32.9979.PubMedCrossRef

Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., et al. (2011). Strategies to identify the Lynch syndrome among patients with colorectal cancer. Annals of Internal Medicine, 155(2), 69–79. doi:10.1059/0003-4819-155-2-201107190-00002.PubMedCentralPubMedCrossRef

Leenen, C. H. M., van Lier, M. G. F., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et al. (2012). Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecologic Oncology, 125(2), 414–420. doi:10.1016/j.ygyno.2012.01.049.PubMedCrossRef

Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158–5164. doi:10.1200/JCO.2007.10.8597.PubMedCrossRef

Lynch, H. T. (1999). Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenetics and Cell Genetics, 86(2), 130–135.PubMedCrossRef

Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 12(2), 93–104. doi:10.1097/GIM.0b013e3181cd666c.PubMedCrossRef

Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.PubMedCentralPubMedCrossRef

Pappa, K. I., Choleza, M., Markaki, S., Giannikaki, E., Kyroudi, A., Vlachos, G., et al. (2006). Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecologic Oncology, 100(3), 596–600. doi:10.1016/j.ygyno.2005.09.029.PubMedCrossRef

Peres, J. (2010). To screen or not to screen for Lynch syndrome. Journal of the National Cancer Institute, 102(18), 1382–1384.

Pinol, V., Castells, A., Andreu, M., Castellvi-Bel, S., Alenda, C., Llor, X., et al. (2005). Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Journal of the American Medical Association, 293(16), 1986–1994. doi:10.1001/jama.293.16.1986.PubMedCrossRef

Ramsoekh, D., Wagner, A., van Leerdam, M., Dooijes, D., Tops, C., Steyerberg, E., et al. (2009). Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, 7(1), 17.PubMedCentralPubMedCrossRef

Resnick, K., Straughn, J. M., Jr., Backes, F., Hampel, H., Matthews, K. S., & Cohn, D. E. (2009a). Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstetrics and Gynecology, 114(3), 530–536. doi:10.1097/AOG.0b013e3181b11ecc00006250-200909000-00008.PubMedCrossRef

Resnick, K. E., Hampel, H., Fishel, R., & Cohn, D. E. (2009b). Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 114(1), 128–134. doi:10.1016/j.ygyno.2009.03.003.PubMedCentralPubMedCrossRef

Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., & Boyd, J. (1993). Genetic instability of microsatellites in endometrial carcinoma. Cancer Research, 53(21), 5100–5103.PubMed

Salvesen, H. B., Kumar, R., Stefansson, I., Angelini, S., MacDonald, N., Smeds, J., et al. (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer, 115(6), 930–934. doi:10.1002/ijc.20702.CrossRef

Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261–269. doi:10.1056/NEJMoa052627.PubMedCrossRef

Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419–428. doi:10.1053/j.gastro.2008.04.026.PubMedCentralPubMedCrossRef

Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. Journal of Molecular Diagnostics, 10(4), 293–300. doi:10.2353/jmoldx.2008.080031.PubMedCrossRef

Shia, J., Stadler, Z., Weiser, M. R., Rentz, M., Gonen, M., Tang, L. H., et al. (2011). Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? The American Journal of Surgical Pathology, 35(3), 447–454. doi:10.1097/PAS.0b013e31820a091d.

Sinicrope, F. A., & Sargent, D. J. (2009). Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology, 21(4), 369–373. doi:10.1097/CCO.0b013e32832c94bd.

Sjursen, W., Haukanes, B. I., Grindedal, E. M., Aarset, H., Stormorken, A., Engebretsen, L. F., et al. (2010). Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. Journal of Medical Genetics, 47(9), 579–585. doi:10.1136/jmg.2010.077677.PubMedCentralPubMedCrossRef

Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology, 137(5), 1621–1627. doi:10.1053/j.gastro.2009.07.039.PubMedCentralPubMedCrossRef

Stormorken, A. T., Clark, N., Grindedal, E., Maehle, L., & Moller, P. (2007). Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scandinavian Journal of Gastroenterology, 42(5), 611–617. doi:10.1080/00365520601010230.PubMedCrossRef

Stupart, D. A., Goldberg, P. A., Algar, U., & Ramesar, R. (2009). Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Disease, 11(2), 126–130. doi:10.1111/j.1463-1318.2008.01702.x.PubMedCrossRef

Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268. doi:10.1093/jnci/djh034.PubMedCentralPubMedCrossRef

Vasen, H., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Diseases of the Colon & Rectum, 34(5), 424–425.CrossRef

Vasen, H., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.PubMedCrossRef

Weissman, S., Burt, R., Church, J., Erdman, S., Hampel, H., Holter, S., et al. (2012). Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 21(4), 484–493. doi:10.1007/s10897-011-9465-7.PubMedCrossRef

Williams, J., & Williams, M. (2011). Informed consent and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(9), 848–849.PubMedCrossRef

Zhang, L. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. Journal of Molecular Diagnostics, 10(4), 301–307. doi:10.2353/jmoldx.2008.080062.PubMedCrossRef

Titel: Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors
verfasst von: Stephanie A. Cohen
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 1/2014
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-013-9603-5

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Large Normal and Intermediate Alleles in the Context of SCA2 Prenatal Diagnosis

Practical Aspects of Recruitment and Retention in Clinical Trials of Rare Genetic Diseases: The Phenylketonuria (PKU) Experience

Expansion of Genetic Services Utilizing a General Genetic Counseling Clinic

NIPT in a Clinical Setting: An analysis of Uptake in the First Months of Clinical Availability

Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors

What’s the Harm? Genetic Counselor Perceptions of Adverse Effects of Genetics Service Provision by Non-Genetics Professionals

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie